Granted Patent
B2
US 12,463,463 · App. 17/425,830 · Granted Nov 4, 2025
Bispecific antibodies and uses thereof
Inventors:
Yue Liu (Hayward, CA); Wenyan Cai (Hayward, CA); Jiadong Shi (Hayward, CA); Zhejun Jia (Hayward, CA)
Assignee:
Ab Therapeutics, Inc.
H02J50/10A61P35/00C07K16/2809C07K16/2827C07K16/2887C07K16/2896H04B5/79H04R25/00A61K2039/505C07K2317/24C07K2317/31C07K2317/56C07K2317/73C07K2317/732C07K2317/734C07K2317/77C07K2317/92H04R2225/31
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This disclosure relates to bispecific antibodies or antigen-binding fragments thereof, wherein the bispecific antibodies or antigen-binding fragments thereof specifically bind to two different antigens with different binding affinities.
Claims (33)
1 . An antibody or antigen-binding fragment thereof that binds to CD3 and CD20 comprising:
a first heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3; and
a first light chain variable region (VL) comprising CDRs 1, 2, and 3;
a second heavy chain variable region (VH) comprising CDRs, 1, 2, and 3; and
a second light chain variable region (VL) comprising CDRs, 1, 2, and 3;
wherein the first VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 22-24, respectively;
the second VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 16-18, respectively; and
the first and second VL CDRs 1, 2, 3 amino acid sequences are set forth in
(SEQ ID NO: 71)
RASSSVSYIX 1 ,
(SEQ ID NO: 29)
ATSNLAS,
and
(SEQ ID NO: 72)
X 2 QWTSX 3 PX 4 T,
respectively,
wherein (a) X 1 is Leu, Pro, Ala, Gly, Glu, Thr, Val, Asp, or Ser, X 2 is Gln, X 3 is Asn, and X 4 is Pro;
(b) X 1 is His, X 2 is Met, X 3 is Asn, and X 4 is Pro;
(c) X 1 is His, X 2 is Gln, X 3 is Ser, Thr, or Val, and X 4 is Pro; or
(d) X 1 is His, X 2 is Gln, X 3 is Asn, and X 4 is Val or Ala.
2 . The antibody or antigen-binding fragment thereof of claim 1 , wherein X 1 is Thr, X 2 is Gln, X 3 is Asn, and X 4 is Pro.
3 . The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment specifically binds to human CD3.
4 . The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment is a bispecific antibody.
5 . The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment specifically binds to human CD20.
6 . An antibody-drug conjugate comprising the antibody or antigen-binding fragment thereof of claim 1 , covalently bound to a therapeutic agent.
7 . The antibody-drug conjugate of claim 6 , wherein the therapeutic agent is a cytotoxic or cytostatic agent.
8 . A method of treating a subject having a CD20+ cancer, the method comprising administering a therapeutically effective amount of a composition comprising the antibody or antigen-binding fragment thereof of claim 1 , to the subject.
9 . The method of claim 8 , wherein the subject has a solid tumor, melanoma, pancreatic carcinoma, a hematological malignancy, Non-Hodgkin's lymphoma, lymphoma, or chronic lymphocytic leukemia.
10 . A method of decreasing the rate of tumor growth, the method comprising
contacting a tumor cell with an effective amount of a composition comprising an antibody or antigen-binding fragment thereof of claim 1 , to the subject.
11 . A method of killing a tumor cell, the method comprising
contacting a tumor cell with an effective amount of a composition comprising the antibody or antigen-binding fragment thereof of claim 1 , to the subject.
12 . A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of claim 1 , and a pharmaceutically acceptable carrier.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 5, 2021
From: LIU, YUE; CAI, WENYAN; SHI, JIADONG; JIA, ZHEJUN
To: AB STUDIO INC.
Reel/Frame 057090/0678 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 5, 2021
From: AB STUDIO INC.
To: AB THERAPEUTICS, INC.
Reel/Frame 057090/0835 →
Continuity (2)
Provisional Application
62797818
· Jan 28, 2019
References Cited (123)
US 4522811A
· Eppstein et al.
· 1985
[cited by applicant]
US 4603112A
· Paoletti et al.
· 1986
[cited by applicant]
US 4676980A
· Segal et al.
· 1987
[cited by applicant]
US 4769330A
· Paoletti et al.
· 1988
[cited by applicant]
US 4777127A
· Suni et al.
· 1988
[cited by applicant]
US 5017487A
· Stunnenberg et al.
· 1991
[cited by applicant]
US 20160287732A1
· Boerman et al.
· 2016
[cited by applicant]
CN 103987405
· 2014
[cited by applicant]
CN 104379169
· 2015
[cited by applicant]
EP 0345242
· 1989
[cited by applicant]
EP 1876236
· 2008
[cited by applicant]
EP 2009101
· 2008
[cited by applicant]
EP 2295468
· 2011
[cited by applicant]
EP 3243840
· 2017
[cited by applicant]
GB 2200651
· 1991
[cited by applicant]
JP 2017507650
· 2017
[cited by applicant]
WO WO8901973
· 1989
[cited by applicant]
WO WO9102805
· 1991
[cited by applicant]
WO WO9627011
· 1996
[cited by applicant]
WO WO2004032832
· 2004
[cited by applicant]
WO WO2004106381
· 2004
[cited by applicant]
WO WO2008077546
· 2008
[cited by applicant]
WO WO2013109279A2
· 2013
[cited by examiner]
WO WO2013126746
· 2013
[cited by applicant]
WO WO2013163427
· 2013
[cited by applicant]
WO WO2013170168
· 2013
[cited by applicant]
WO WO2014047231
· 2014
[cited by applicant]
WO WO2014189973
· 2014
[cited by applicant]
WO WO2015006749A2
· 2015
[cited by examiner]
WO WO2015143079
· 2015
[cited by applicant]
WO WO2016077505
· 2016
[cited by applicant]
WO WO2016086189
· 2016
[cited by applicant]
WO WO2016110267
· 2016
[cited by applicant]
WO WO2016110576
· 2016
[cited by applicant]
WO WO2016111751
· 2016
[cited by applicant]
WO WO2016182751
· 2016
[cited by applicant]
WO WO2017010874
· 2017
[cited by applicant]
WO WO2017055547
· 2017
[cited by applicant]
WO WO2017106462
· 2017
[cited by applicant]
WO WO2018093821
· 2018
[cited by applicant]
WO WO2019028125
· 2019
[cited by applicant]
MacCallum et al., Antibody-antigen interactions: contact analysis and binding site topography; 1996, J. Mol. Biol., 262: 732-745. (Year: 1996).
[cited by examiner]
Chen et al., Generation and analysis of random point mutations in an antibody CDR2 sequence: many mutated antibodies lose their ability to bind, 1992, Journal of Experimental Medicine, 176: 855-866. (Year: 1992).
[cited by examiner]
Koenig et al., Mutational landscape of antibody variable domains reveals a switch modulating the interdomain conformational dynamics and antigen binding; 2017, PNAS, 114(4): E486-495. (Year: 2017).
[cited by examiner]
Bortoletto et al., Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells; 2002, Eur. J. Immunol., 32:3102-3107. (Year: 2002).
[cited by examiner]
EP Extended Search Report in European Appln. No. 20749497.0, dated Feb. 23, 2023, 15 pages.
[cited by applicant]
GenBank Accession No. AAV65828.1, “anti-human CD3 12F6 immunoglobulin heavy chain variable region precursor, partial [Mus musculus],” Jun. 7, 2004, 2 pages.
[cited by applicant]
Xiong et al., “Study on the biological activity of anti-CD3/anti-CD20 dia body,” Chin J Microbiol Immunol, Nov. 2001, 21(6):627-631 (with English abstract).
[cited by applicant]
CN Office Action in Chinese Appln. No. 201880062833.7, mailed on Nov. 1, 2023, 16 pages (with English translation).
[cited by applicant]
EP Office Action in European Appln. No. 22160823.5, mailed on Jan. 25, 2024, 5 pages.
[cited by applicant]
CN Office Action in Chinese Appln. No. 201880062833.7, dated Mar. 1, 2023, 20 pages (with English translation).
[cited by applicant]
EP Office Action in European Appln. No. 18840836.3, dated Mar. 14, 2023, 7 pages.
[cited by applicant]
JP Japanese Office Action in Japanese Appln. No. 2020-529100, dated Mar. 1, 2023, 11 pages.
[cited by applicant]
Macor et al., “Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice,” Leukemia, Feb. 2015, 29(2):406-14.
[cited by applicant]
Zhang et al., “Relationship between Bcl-2, p53 and CD55 expression and outcome of rituximab in treatment of DLBCL patients,” Chinese Journal of Clinicians, 4(12), Jan. 2010, pages (English translation).
[cited by applicant]
Cai et al., “Biological acivity validation of a computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of action,” Antibody Therapeutics, 2021, 4:4:228-241.
[cited by applicant]
Abhinandan, et al. “Analysis and improvements to Kabat and structurally correct numbering of antibody variable domains,” Molecular Immunology, 2008, 45(14):3832-3839.
[cited by applicant]
Brennan et al., “Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments,” Science, 1985, 229:81-83.
[cited by applicant]
Chothia et al., “Conformations of immunoglobulin hypervariable regions,” Nature, 1989, 342(6252):877-83.
[cited by applicant]
Cohen, “Naked DNA points way to vaccines,” Science, 1993, 259(5102):1691-1692.
[cited by applicant]
EP Extended European Search Report in European Appln No. 18840836.3, dated Jun. 15, 2021, 17 pages.
[cited by applicant]
EP Extended European Search Report in European Appln No. 18840836.3, dated Mar. 3, 2021, 11 pages.
[cited by applicant]
Fisher-Hoch et al., “Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene,” Proc. Natl. Acad. Sci. USA, 1989, 86(1):317-321.
[cited by applicant]
Flexner et al., “Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2,” Vaccine, 1990,8(1):17-21.
[cited by applicant]
Flexner et al., “Vaccinia virus expression vectors,” Ann. N.Y. Acad Sci., 1989, 569:86-103.
[cited by applicant]
Guzman et al., “Efficient and selective adenovirus-mediated gene transfer into vascular neointima,” Circulation, 1993, 88:2838-2848.
[cited by applicant]
Guzman et al., “Efficient gene transfer into myocardium by direct injection of adenovirus vectors,” Cir. Res., 1993, 73:1202-1207.
[cited by applicant]
International Preliminary Report on Patenability in Appl. No. PCT/US2020/015311, dated Aug. 12, 2021, 5 pages.
[cited by applicant]
International Preliminary Report on Patentability in Appln. No. PCT/US2018/044778, dated Feb. 4, 2020, 16 pages.
[cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2018/0447788, dated Jan. 10, 2019, 19 pages.
[cited by applicant]
Irani, et al. “Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases.” Molecular immunology, 2015, 67(2):71-182.
[cited by applicant]
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,” Nature, 1986, 321:522-525.
[cited by applicant]
Jones et al., “The INNs and outs of antibody nonproprietary names,” Mabs, 2016, 8(1):1-9.
[cited by applicant]
Kass-Eisler et al., “Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo,” Proc. Natl. Acad. Sci. USA, 1993, 90(24):11498-11502.
[cited by applicant]
Kohler et al., “Continuous cultures of fused cells secreting antibody of predefined specificity,” Nature, 1975, 256(5517):495-497.
[cited by applicant]
Kolls et al., “Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer,” Proc. Natl. Acad. Sci. USA, 1994, 91:215-219.
[cited by applicant]
Kozbor et al., “The production of monoclonal antibodies from human lymphocytes,” Immunol. Today, 1983, 4(3):72.
[cited by applicant]
Li et al., “Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions,” Immunology, 2005, 116(4):487-498.
[cited by applicant]
Martin et al., “Molecular modeling of antibody combining sites,” Methods Enzymol., 1991, 203:121-53.
[cited by applicant]
Martin, “Protein sequence and structure analysis of antibody variable domains,” Antibody engineering, Springer Berlin Heidelberg, 2001, 422-439.
[cited by applicant]
Morea et al., “Antibody structure, prediction and redesign,” Biophys Chem., 1997, 68(1-3):9-16.
[cited by applicant]
Morea et al., “Conformations of the third hypervariable region in the VH domain of immunoglobulins,” J Mol Biol., 1998, 275(2):269-94.
[cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2020/047605, dated, Feb. 19, 2021, 16 pages.
[cited by applicant]
PCT International Written Opinion in Appln. No. PCT/US20/15311, dated Apr. 23, 2020, 3 pages.
[cited by applicant]
Ponomarenko and Bourne, “Antibody-protein interactions: benchmark datasets and prediction tools evaluation,” BMC Structural Biology, 2007, 7:64.
[cited by applicant]
Ridgway et al., “‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization.” Protein Engineering, 1996, 9(7):617-621.
[cited by applicant]
Ridgway et al., “Identification of a human anti-CD55 single-chain Fv by subtractive panning of a phage library using tumor and nontumor cell lines,” Cancer Res., 1999, 59 (11):2718-2723.
[cited by applicant]
Riechmann et al., “Reshaping human antibodies for therapy,” Nature, 1988, 332(6162):323-327.
[cited by applicant]
Rosenfeld et al., “Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo,” Science, 1991, 252(5004):431-434.
[cited by applicant]
Silva et al. “The S228P mutation prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation.” Journal of Biological Ch…
[cited by applicant]
Smith et al., “A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys,” Scientific Reports, Dec. 2015, 5:17943.
[cited by applicant]
Ulmer et al., “Heterologous protection against influenza by injection of DNA encoding a viral protein,” Science, 1993, 259(5102):1745-1749.
[cited by applicant]
Verhoeyen et al., “Reshaping human antibodies: grafting an antilysozyme activity,” Science, 1988, 239(4847):1534-1536.
[cited by applicant]
Vidarsson, et al, “IgG subclasses and allotypes: from structure to effector functions.” Frontiers in immunology, 2014, 5.
[cited by applicant]
Wu et al., “An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity,” J. Exp. Med., 1970, 132(2):211-250.
[cited by applicant]
Yue, “Development of novel therapeutic antibodies via computational design,” Jul. 2018, 31 pages.
[cited by applicant]
Extended Search Report in European Appln No. 22160823.5, dated Sep. 30, 2022, 16 pages.
[cited by applicant]
Barthelemy et al., “Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains,” Journal of Biological Chemistry, 2008, 283:3639-3654.
[cited by applicant]
Beiboer et al., “Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent,” Journal of Molecul…
[cited by applicant]
Choi et al., “Predicting antibody complementarity determining region structures without classification,” Molecular BioSystems, 2011, 7:3327-334.
[cited by applicant]
De Genst et al., “Antibody repertoire development in camelids,” Developmental and Comparative Immunology, 2006, 30:187-98.
[cited by applicant]
Griffiths et al., “Human anti-self antibodies with high specificity from phage display libraries.,” The EMBO Journal, 1993, 12:725-734.
[cited by applicant]
Klinnka et al., “Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning,” British Journal of Cancer, 2000, 83:252-260.
[cited by applicant]
Malia et al., “Epitope mapping and structural basis for the recognition of phosphorylated tau by the anti-tau antibody AT8,” Proteins, 2016; 84:427-434.
[cited by applicant]
Ward et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted from
[cited by applicant]
Budde et al., “Mosunetuzumab, a full-length bispecific CD20/CD3 antibody, displays clinical activity in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL): interim safety and efficacy results from a phase 1 study,” B…
[cited by applicant]
EP European Search Report in European Appln. No. 20749497.2, dated Nov. 18, 2022, 19 pages.
[cited by applicant]